Abstract
Abundant volumes of clinical laboratory test results available within Electronic health records (EHRs) are essential for differential diagnosis, treatment monitoring, and outcome evaluation. LOINC2HPO is a recently developed deep phenotyping approach to transform laboratory test results into the Human Phenotype Ontology (HPO) terms. Here, we deployed the approach on a large EHR dataset from the Sema4 Data Warehouse to build patient phenotypic journeys at scale. Among 1.07 billion laboratory test results, we successfully transformed 774 million (72.5%) into HPO-coded phenotypes and built a patient phenotypic journey for over 2.2 million patients. First, a global analysis of patient phenotypic journeys revealed a longitudinal increase in patients with genitourinary system abnormality. The analysis also revealed abnormal phenotypes with strong racial patterns. Second, using severe asthma as an example case, we identified abnormal phenotypes in the past three years that were correlated with asthma progression to severe state. Lastly, we demonstrated that converting laboratory test results into HPO terms resulted in limited information loss. Our study demonstrated that the phenotypic journey framework opens the way to characterize phenotypic trajectories in population level and screen biomarkers for translational research.
Competing Interest Statement
X.A.Z., K.L., L.J., Z.L., L.A., T.J., M.K.H., Q.P., W.O., G.S., E.S., and X.W. are employed by Sema4 OpCo, Inc..
Funding Statement
The study was funded by Sema4 OpCo, Inc. P.N.R. is funded by National Institute of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor should any endorsements be inferred by NIH or the U.S. Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Sema4 OpCo, Inc waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to patient privacy protection, the dataset is not publicly accessible. Data access requests should be addressed to Sema4 (https://support.sema4.com/hc/en-us/requests/new).
